Brain Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with a solid (non-blood) cancer that has been confirmed by laboratory testing, and who have been referred for whole-brain radiation therapy for treatment or prevention purposes.
- People who are in reasonably good general health, as measured by standard medical scoring systems (a score of 0–2 on the ECOG scale, or at least 70% on the Karnofsky scale — confirm with trial site if unsure what these mean for your situation).
- People whose cancer has spread to the brain in no more than three separate spots, with each spot being no larger than 4 cm (roughly 1.5 inches) across.
Who may not be able to join:
- People whose brain scans show cancer spread within 5 mm (less than a quarter of an inch) of the hippocampus, a specific area of the brain.
- People who show signs that the cancer may have spread to the lining of the brain or spinal cord (a condition called leptomeningeal disease — confirm with trial site).
- People who have previously received any form of radiation therapy to the brain or head area for any reason, including a specialised type called stereotactic radiosurgery.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: +886-33281200
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
The primary endpoint is delayed recall, as determined by the change/decline in verbal memory (WMS III- Word List score) from the baseline assessment to 4 months after the start of HS-WBRT.; The primary endpoint is delayed recall, as determined by the change/decline in non-verbal memory (WMS III- Visual Reproduction score) from the baseline assessment to 4 months after the start of HS-WBRT.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.